| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.36 | 0.003 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.097 | 0.006 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.088 | 0.007 |